Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ANIK 
Anika Therapeutics Inc (ANIK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: ANIK (1-star) is a SELL. SELL since 3 days. Simulated Profits (-2.66%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16
1 Year Target Price $16
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.79% | Avg. Invested days 52 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 136.86M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 3 | Beta 0.51 | 52 Weeks Range 7.87 - 18.37 | Updated Date 12/11/2025 |
52 Weeks Range 7.87 - 18.37 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -29.29% | Operating Margin (TTM) -11.62% |
Management Effectiveness
Return on Assets (TTM) -3.5% | Return on Equity (TTM) -8.73% |
Valuation
Trailing PE - | Forward PE 37.04 | Enterprise Value 105609657 | Price to Sales(TTM) 1.21 |
Enterprise Value 105609657 | Price to Sales(TTM) 1.21 | ||
Enterprise Value to Revenue 0.94 | Enterprise Value to EBITDA 175.12 | Shares Outstanding 14421219 | Shares Floating 10770055 |
Shares Outstanding 14421219 | Shares Floating 10770055 | ||
Percent Insiders 4.88 | Percent Institutions 85.71 |
Upturn AI SWOT
Anika Therapeutics Inc
Company Overview
History and Background
Anika Therapeutics Inc. was founded in 1994 with a focus on developing and commercializing proprietary hyaluronic acid (HA)-based products for joint pain and inflammation. Key milestones include the development of its first HA-based viscosupplementation products for osteoarthritis, followed by expansions into sports medicine, orthopedics, and regenerative medicine. The company has evolved from a product development entity to a commercial-stage company with a diversified portfolio.
Core Business Areas
- Joint Preservation and Restoration: Focuses on products designed to alleviate pain and restore function in joints, primarily through viscosupplementation and cartilage repair technologies. This includes hyaluronic acid-based injections for osteoarthritis.
- Advanced Wound Management: Develops and markets advanced wound care products, often leveraging its HA technology to promote healing and reduce scarring in chronic and acute wounds.
- Ortho-Biologics and Regenerative Medicine: Invests in research and development of biologic solutions and regenerative medicine approaches aimed at healing and tissue repair, potentially expanding beyond current indications.
Leadership and Structure
Anika Therapeutics Inc. is led by a management team comprising experienced professionals in the biotechnology and pharmaceutical industries. The organizational structure is designed to support product development, clinical trials, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Cingalu00ae: A single-injection hyaluronic acid (HA) viscosupplementation product for osteoarthritis knee pain that also contains a corticosteroid to provide rapid pain relief. Competitors include other HA viscosupplements like Synvisc-One (Sanofi) and Euflexxa (Subiton), as well as other pain relief injections.
- Orthoviscu00ae: A multi-injection HA viscosupplementation therapy for osteoarthritis knee pain. Competitors include Synvisc (Sanofi), Hyalgan (Fidia Pharma), and Supartz (Seikagaku Corporation).
- Triviscu00ae: Another multi-injection HA viscosupplementation therapy for osteoarthritis knee pain, similar in application to Orthovisc. Competitors are the same as for Orthovisc.
- VascuSTIMu2122: A wound healing product utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) to promote healing in diabetic foot ulcers. Competitors include products based on other growth factors or advanced wound care technologies.
Market Dynamics
Industry Overview
Anika Therapeutics Inc. operates within the highly competitive orthopedic and regenerative medicine markets, particularly in the treatment of osteoarthritis and wound care. The market is driven by an aging global population, increasing prevalence of chronic diseases like osteoarthritis and diabetes, and advancements in biologic and minimally invasive treatments.
Positioning
Anika Therapeutics Inc. is positioned as a commercial-stage company with a portfolio of established viscosupplementation products and a growing focus on innovative regenerative medicine and advanced wound care solutions. Its competitive advantages lie in its proprietary HA technology, established commercial infrastructure, and ongoing research into novel therapeutic applications.
Total Addressable Market (TAM)
The total addressable market for osteoarthritis treatments, including viscosupplementation and other therapies, is substantial, estimated to be in the tens of billions of dollars globally. The wound care market, especially for chronic wounds, is also significant. Anika Therapeutics Inc. aims to capture a meaningful share of these markets by offering differentiated products that address unmet clinical needs.
Upturn SWOT Analysis
Strengths
- Proprietary hyaluronic acid technology
- Established commercial presence in viscosupplementation
- Diverse product pipeline with potential for growth
- Experienced management team
- Focus on high-growth therapeutic areas
Weaknesses
- Reliance on a few key products for revenue
- Intense competition within its market segments
- Need for continued investment in R&D to drive future growth
- Potential challenges in navigating complex regulatory pathways for new products
Opportunities
- Expansion into new geographic markets
- Development and commercialization of next-generation regenerative medicine products
- Strategic partnerships and collaborations
- Increasing demand for minimally invasive orthopedic procedures
- Growth in the biologics market
Threats
- Intensifying competition from larger pharmaceutical companies
- Pricing pressures and reimbursement challenges
- Emergence of disruptive technologies
- Changes in regulatory requirements
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- Seikagaku Corporation (SKGYF)
- Fidia Pharma (private)
- Smith & Nephew (SNN)
- Stryker Corporation (SYK)
Competitive Landscape
Anika Therapeutics Inc. faces significant competition from established global pharmaceutical and medical device companies. Its competitive advantages are its specialized focus on HA-based solutions and its agility in developing niche products. However, larger competitors often have greater resources for marketing, sales, and R&D, posing a challenge to market share expansion.
Growth Trajectory and Initiatives
Historical Growth: Anika Therapeutics Inc. has demonstrated growth through the expansion of its product lines and market reach in viscosupplementation. Recent years have seen increased focus on diversifying into regenerative medicine and advanced wound care.
Future Projections: Future growth projections for Anika Therapeutics Inc. are contingent on the successful development and commercialization of its pipeline products, market penetration in new therapeutic areas, and continued adoption of its existing offerings. Analyst estimates would provide quantitative projections for revenue and earnings growth.
Recent Initiatives: Recent strategic initiatives may include the launch of new products, clinical trial advancements, strategic partnerships, and potential acquisitions aimed at expanding its technology platform and market access.
Summary
Anika Therapeutics Inc. is a commercial-stage company in the regenerative medicine and orthopedics sector, with strengths in hyaluronic acid-based joint pain treatments. While it has established products, it faces intense competition and requires continued R&D investment. Opportunities lie in market expansion and novel product development, but threats from larger players and regulatory changes are present. The company's future success hinges on its ability to innovate and effectively compete in a dynamic market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Websites
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (general industry data)
- SEC Filings (10-K, 10-Q)
Disclaimers:
This JSON output is generated for informational purposes only and should not be considered financial advice. Financial data and market share figures are estimates and may vary. Investment decisions should be based on thorough personal research and consultation with a qualified financial advisor. Information is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 288 | Website https://www.anika.com |
Full time employees 288 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.